Lifestyle intervention prevents or delays the conversion from impaired glucose tolerance (IGT) to type 2 diabetes. However, many subjects fail to achieve and/or maintain long-term weight loss and to follow a regular exercise regimen may require pharmacologic therapy. Insulin resistance in liver, muscle and fat, along with impaired beta-cell function, plays a central role in the pathogenesis of type 2 diabetes. Insulin sensitising drugs, including metformin and the thiazolidinediones, have significantly reduced the conversion rate of IGT to type 2 diabetes in subjects in several large, well designed clinical trials. Insulin-sensitising drugs are likely to play an important role in future strategies for diabetes prevention.
DeFronzo RALilly Lecture. The triumvariate: beta cell, muscle, liver. A collusion responsible for NIDDMDiabetes1988;37:667-87.
2.
DeFronzo RAPathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev1997 ;5: 177-269.
3.
DeFronzo RA, Ferrannini E., Simonson DCFasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake . Metabolism1989;38:387-95.
4.
Groop LC, Bonadonna RC, Del Prato S., Ratheiser K., Zyck K., DeFronzo RAEffect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance . J Clin Invest1989;84:205-13.
5.
Gastaldelli A., Baldi S., Pettiti M. et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes2000;49:1367-73.
6.
Magnusson I. , Rothman DL, Katz LD, Shulman RG, Shulman GIIncreased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest1992;90:1323-7.
7.
Mitrakou A., Kelley D., Mokan M. et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med1992;326:22-9.
8.
Bonadonna RC , Del Prato S., Bonora E. et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM . Diabetes1996;45:915-25.
9.
DeFronzo RA, Gunnarsson R., Bjorkman O., Olsson M., Wahren J.Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus. J Clin Invest1985;76:149-55.
10.
Shulman GI, Rothman DL, Jue T., Stein P., DeFronzo RA, Shulman RGQuantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes by 13C nuclear magnetic resonance spectroscopy . N Engl J Med1990;322:223-8.
11.
Reaven GM, Hollenbeck CB, Chen YDI.Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance . Diabetologia1989;32:52-5.
12.
Gulli G., Ferrannini E., Stern M., Haffner S., DeFronzo RAThe metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes1992;41:1575-86.
13.
Cusi K., Maezono K., Osman A. et al. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest2000;105:311-20.
14.
Pratipanawatr W., Pratipanawa T., Cusi K. et al. Skeletal muscle insulin resistance in normoglycaemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation . Diabetes2001;50:2572-8.
15.
Shepherd PR , Kahn B.Mechanisms of disease: glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus . N Engl J Med1999;341:248-57.
16.
Mandarino LJ , Printz RL, Cusi KA et al. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle . Am J Physiol1995;269:E701-E708.
17.
Polonsky KS , Sturis J., Bell GINon-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med1996;334:777-83.
18.
Kahn SEClinical Review 135. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab2001;86:4047-58.
19.
Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PHSequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet1989;1:1356-9.
20.
Brunzell JD , Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab1976;42:222-9.
21.
Luzi L., DeFronzo RAEffect of loss of first phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol1989;20:E241-E246.
22.
Yalow RS, Benson SAImmunoassay of endogenous plasma insulin in man. J Clin Invest1960;39:1157-75.
23.
DeFronzo RAPharmacologic therapy for type 2 diabetes mellitus . Ann Internal Med2000;133:73-4.
24.
Eriksson KF , Lingarde F.Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia1991;34: 891-8.
25.
Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Quing IGT and diabetes study. Diabetes Care1997;20:537-44.
26.
Tuomilehto J., Lindstrom J., Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343-50.
27.
Diabetes Prevention ProgramResearch Group.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med2002;346:393-403.
28.
McGarry JD: Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes2002 ;51:7-18.
29.
Boden G.Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes1997;46:3-10.
30.
Reaven GM: The fourth musketeer-from Alexandre Dumas to Claude Bernard. Diabetologia1995;38:3-13.
31.
Groop LC, Bonadonna RC, Del Prato S., Ratheiser K., Zyck K., DeFronzo RAEffect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance . J Clin Invest1989;84:205-13.
32.
Reaven GMBanting Lecture: role of insulin resistance in human disease. Diabetes1988;37:595-607.
33.
Kashyap S., Belfort R., Pratipanawatr T. et al. Effect of a chronic elevation in plasma free fatty acids on insulin secretion and action in nondiabetic offspring with a strong family history of T2DM. Diabetes2002; 51(suppl 2):A12.
34.
McGarry JDBanting Lecture2001. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes2002;51:7-18. 35. Ferrannini E., Barrett EJ, Bevilacqua S., DeFronzo RAEffect of fatty acids on glucose production and utilization in manJ Clin Invest1983;72: 1737-47.
35.
Thiebaud D. , DeFronzo RA, Jacot E. et al. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism1982 ;21:1128-36.
36.
Miyazaki Y. , Glass L., Triplitt C. et al. Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients. Diabetologia2001;44:2210-19.
37.
Cusi K., Consoli A., DeFronzo RAMetabolic effects of metformin on glucose and lactate metabolism in NIDDM . J Clin Endo Metab1996;81: 4059-67.
38.
Cusi K., DeFronzo RAMetformin: a review of its metabolic effects. Diabetes Rev1998;6:89-131.
39.
Johnson AB, Webster JM, Sum CF et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism1993; 42:1217-22.
40.
Stumvoll M. , Nurjhan N., Perriello G., Dailey G., Gerich JEMetabolic effects of metformin in non-insulin-dependent diabetes mellitus. Engl J Med1995;333:550-4.
41.
DeFronzo RA , Goodman AMThe Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med1995;333:541-9.
42.
Widen E., Erikson J., Groop L.Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycaemic first degree relatives of patients with NIDDM. Diabetes1992;41:354-8.
43.
Wollen N., Bailey CJInhibition of hepatic gluconeogenesis by metformin: synergism with insulin . Biochem Pharmacol1988;37:4353-8.
44.
Rossetti L. , DeFronzo RA, Gherzi R. et al. Insulin receptor tyrosine kinase activity and in vivo insulin action in diabetic rats. Effect of metformin treatment . Metabolism1990;39:425-35.
45.
Stith BJ, Goalstone ML, Espinoza R., Mossel C., Roberts D., Wiernsperger N.The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinol1996;137:2990-9.
46.
Stith B., Woronoff K., Wiernsperger N.Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem Pharmacol1998;55:533-6.
47.
Klip A., Leiter LACellular mechanism of action of metformin. Diabetes Care1990;13:696-704.
48.
Galuska D., Nolte LA, Zierath JR, Wallberg-Henriksson H.Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia1994;37:826-32.
49.
Detaille D. , Wiernsperger N., Devos P.Potentiating effect of metformin on insulin-induced glucose uptake and glycogen metabolism with Xenopus oocytes. Diabetologia1998;41:2-8.
50.
Zhou G., Myers R., Li Y. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest2001;108:1167-74.
51.
Mithieux G. , Guignot L., Bordet J.- C. Wiernsperger N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes2002;51:139-43.
52.
UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet1998;352:854-65.
53.
Nolan JJ, Ludvik B., Beerdsen P., Joyce M., Olefsky J.Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med1994 ;331:1188-93.
54.
Inzucchi SE , Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus . N Engl J Med1998;338:867-72.
55.
Meyer MM, Levin K., Grimmsmann T. et al. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycaemic subjects at risk for the development of type 2 diabetes. Diabetes2002;51:2691-7.
56.
Miyazaki Y. , Mahankali A., Matsuda M. et al. Improved glycaemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care2001;24:710-19.
57.
Miyazaki Y. , Mahankali A., Matsuda M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients . J Clin Endocrinol Metab2002;87:2784-91.
58.
Miyazaki Y. , He H., Mandarino LJ, DeFronzo RARosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients . Diabetes2003 (in press).
59.
Mayerson AB , Hundal RS, Dufour S. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes2002;51:797802.
60.
Wolffenbuttel BH, Sels JP, Huijberts MSRosiglitazone. Expert Opin Pharmacother2001;2:467-78.
61.
D Chilcott J., Tappenden P., Jones ML, Wight JPA systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther2001;23:1792-823.
62.
Mudaliar S. , Henry RRNew oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med2001;52:239-57.
63.
Miyazaki Y. , Matsuda M., DeFronzo RADose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes mellitus. Diabetes Care2002;25:517-23.
64.
Finegood DT , McArthur MD, Kojwang D., Thomas MJ, Topp BG, Leonard T., Buckingham REBeta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes2001;50:1021-9.
65.
Higa M., Zhou YT, Ravazzola M., Baetens D., Orci L., Unger RHTroglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Nat Acad Sci USA1999;96: 11513-18.
66.
Kim YB, Ciaraldi TP, Kong A. et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p 110 β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes2002 ;51:443-8.
67.
Buchanan TA , Xiang AH, Peters RKPreservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes2002;51:2796-803.
68.
Antonucci T. , Whitcomb R., McClain R., Lockwood D.Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone . Diabetes Care1997;20:188-93.
69.
Cavaghan MK , Ehrmann DA, Byrne MM, Polonsky KSTreatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest1997; 100:530-7.
70.
Gastaldelli A., Miyazaki Y., Pettiti M. et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab2002;87: 5098-103.
71.
Bjorntorp P.Metabolic implications of body fat distribution . Diabetes Care1991;14:1132-43.
72.
Miyazaki Y. , Hardies LJ, Wajcberg E. et al. Effect of pioglitazone on liver fat content, abdominal fat distribution, and insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes2002;51(suppl 2):A69.
73.
Bajaj M., Suraamornkul S., Pratipanawatr T. et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes mellitus. Diabetes2003 (in press).
74.
Miyazaki Y., Hardies JL, Wajcberg E. et al. Effect of pioglitazone on liver fat content, abdominal fat distribution, and insulin sensitivity in type 2 diabetic patients. Diabetes2002;51(suppl 2):A69.
75.
Ryysy L., Hakkinen AM, Goto T. et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes2000;49:749-58.
76.
Krssak M., Falk Petersen K., Dresner A. et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia1999;42:113-16.
77.
Stein DT, Szczepanik L., Dobbins R., McGarry JDIncreasing intramyocellular triglyceride stores are associated with impaired glucose tolerance and NIDDM. Diabetes1999 ;48(suppl 1):A287.
Kelley DE, Goodpaster B., Wing RR, Simoneau JASkeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol1999 ;277:E1130-E1141.
80.
Greco AV, Mingrone G., Giancaterini A. et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes2002; 51:144-51.
81.
Perseghin G. , Scifo P., De Cobelli F. et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes1999;48:1600-06.
82.
Khan MA, St. Peter JV, Xue JLA prospective, randomised comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care2002;25:708-11.
83.
de Souza CJ , Eckhardt M., Gagen K. et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance . Diabetes2001 ;50:1863-71.
84.
Kelley IE, Walsh K., Han TS, Lean MEJ.Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care1999;22:288-93.
85.
Kawai T., Takei I., Oguma Y. et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism1999;48: 1102-07.
86.
Pan DA, Lillioja S., Kriketos AD et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes1997;46:983-8.
87.
Kelley DE, Mandarino LJFuel selection in human skeletal muscle in insulin resistance. Diabetes2000;49:677-83.
88.
Itani SI, Ruderman NB, Schmieder F., Boden G.( Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes2002;51:2005-11.
89.
Ellis BA, Poynten A., Lowy AJ et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol2000;279:E554-E560.
90.
De Fea K., Roth RAProtein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612 . Biochemistry1997;36:12939-47.
91.
Ravichandran LV, Esposito DL, Chen J., Quon MJPKC-zeta phosphorylates IRS-1 and impairs its ability to activate P-3-kinase in response to insulin . J Biol Chem2001;276:3543-9.
92.
Faergeman NJ , Knudsen J.Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signaling. Biochem J1997;323:1-12.
Thompson AL , Cooney GJAcyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance . Diabetes2000;49:1761-4.
95.
Tippett PS, Neet KEAn allosteric model for the inhibition of glucokinase by long chain acyl coenzyme A. J Biol Chem1982;257:14846-52.
96.
Schmitz-Peiffer C., Craig DL, Biden TJCeramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem1999;274:24202-10.
97.
Unger RHLipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes1996;45:273-83.
98.
Shimabukuro M., Zhou YT, Levi M., Unger RHFatty acid induced beta cell apoptosis. Proc Natl Acad Sci1998 ;95:2498-502.
99.
McGarry JD : Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes2002;51:7-18.
Rossetti L. , Smith D., Shulman GI, Papachristou D., DeFronzo RACorrection of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin. J Clin Invest1987;79:1510-15.
102.
Kahn B., Shulman GI, DeFronzo RA, Cushman S., Rossetti L.Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest1991;87: 561-70.
103.
Rossetti L. , Shulman GI, Zawalich W., DeFronzo RAEffect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest1987;80:1037-44.
104.
Rossetti L. , Giaccari A., DeFronzo RAGlucose toxicity. Diabetes Care-Reviews1990;13:610-30.
105.
Massillon D., Barzailai N., Hawkins M., Prus-Wetheimer D., Rossetti L.Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes1997;46:153-7.
106.
Leahy JL, Cooper HE, Weir GCImpaired insulin secretion associated with near normoglycemia. Diabetes1987;36:459-64.
107.
Chiasson JL , Josse RG, Gomis R., Hanefeld M., Karasik A., Laakso M.STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial . Lancet2002;359: 2072-7.
108.
Sartor G., Schersten B., Carlstrom S., Melander A., Norden A., Persson G.Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes1980;29:41-9.
109.
DeFronzo RA , Sherwin RS, Hendler R., Felig P.Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding . J Clin Invest1978;62:204-13.
110.
Henry RR, Wallace P., Olefsky JMEffects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes1986;35:990-8.
111.
Kelley DEEffects of weight loss on glucose homeostasis in NIDDM. Diabetes Reviews1995;3:366-77.
112.
Sjostrom L., Torgeson JS, Boldrin M.XENDOS (XENical in the prevention of Diabetes in Obese Subjects): a landmark study. 9th International Congress on Obesity, Sau Paulo, Brazil, August 26, 2002.
113.
Freeman DJ , Norrie J., Sattar N. et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation2001;103:357-62.
114.
Yusef S., Gerstein H., Hoogwerf B. et al., for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA2001;286:1882-5.
115.
The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients . N Engl J Med2000;342:145-53.
116.
Hansson L. , Lindholmn L., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet1999 ; 353:611-16.
117.
Shiuchi T. , Cui T., Wu L. et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension2002;40:329-34.
118.
Folli F., Kahn C., Hansen H., Bouchie J., Feener E.Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: a potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest1997;100:2158-69.
119.
Hsueh W.Treatment of type 2 diabetic nephropathy by blockade of the rennin-agiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. Cur Opin Pharm2002;2:182-8.
120.
Holst J., Orskov C.Incretin hormones - an update. Scand F Clin Lab Invest2001;234:75-85.
Vella A., Shah P., Basu R., Basu A., Holst JJ, Rizza R.Effect of glucagon-like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes2000;49:611-17.
125.
Vaag AA, Holst JJ, Volund A., Beck-Nielsen HBGut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagons-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol1996; 135:425-32.
126.
Fineman MS , Bicsak T., Shen L. et al. AC2993 (synthetic exendin-4) added to existing metformin (Met) and/or sulfonylurea (SFU) treatment improved glycaemic control in patients with type 2 diabetes (DM2) during 28 days of treatment . Diabetes2002;51(suppl 2):A85.
127.
Stamler R. , Stamler J., Lindberg HA et al. Asymptomatic hyperglycemia and coronary heart disease in middle-aged men in two employed populations in Chicago. J Chronic Diseases1979;32:805-15.
128.
Yarnell JW , Pickering JE, Elwood PC et al. Does non-diabetic hyperglycemia predict future IHD? Evidence from the Caerphilly and Speedwell studies. J Clin Epidemiol1994;47:383-8.
129.
Balkau B., Shipley M., Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care1998;21:360-7.
130.
Butler MU, Ostrander LD Jr, Carman WJ, Lamphlear DEMortality from coronary heart disease in the Tecumseh Study: long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol1985;121:541-7.
131.
Stratton IM , Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405-12.
132.
DeFronzo RA , Ferrannini E.Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ASCVD . Diabetes Care-Reviews1991;14:173-94.
133.
Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care2001;24: 683-9.
134.
Yip J. , Facchini FS, Reaven GMResistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab1988;83:2773-6.
135.
Zavaroni I. , Bonini L., Gasparini P. et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism1999;48:989-94.
136.
Golden SH, Folsom AR, Coresh J., Sharrett AR, Szklo M., Brancati F.Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: The Atherosclerosis Risk in Communities Study. Diabetes2002;51:3069-76.
137.
Plutzsky J.Peroxisome proliferators-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms . Current Atherosclerosis Reports2000;2:327-35.
138.
Hsueh WA, Law REInsulin signaling in the arterial wall. Am J Cardiol1999;84:21J-24J.
139.
Law RE , Meehan WP, Xi X-P et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest1996;98:1897-905.
140.
Minamikawa E.J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H.Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes . J Clin Endocrinol Metab1998;83:1818-20.
141.
Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., Nakamura Y.Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab2001;86:3452-6.
142.
Takagi T., Akasaka T., Yamamuro A. et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol2000;36:1529-35.
